When.com Web Search

  1. Ads

    related to: potassium permanganate indications for diabetes treatment

Search results

  1. Results From The WOW.Com Content Network
  2. Potassium permanganate (medical use) - Wikipedia

    en.wikipedia.org/wiki/Potassium_permanganate...

    Potassium permanganate is used as a medication for a number of skin conditions. [2] This includes fungal infections of the foot, impetigo, pemphigus, superficial wounds, dermatitis, and tropical ulcers. [3] [2] For tropical ulcers it is used together with procaine benzylpenicillin. [2] [3] It can be applied as a soaked dressing or a bath. [2]

  3. Potassium permanganate - Wikipedia

    en.wikipedia.org/wiki/Potassium_permanganate

    Potassium permanganate is used extensively in the water treatment industry. It is used as a regeneration chemical to remove iron and hydrogen sulfide (rotten egg smell) from well water via a "manganese greensand" filter.

  4. WHO Model List of Essential Medicines - Wikipedia

    en.wikipedia.org/wiki/WHO_Model_List_of...

    6.5.5.1.1 Medicines for the treatment of 1st stage African trypanosomiasis. ... 18.5 Medicines for diabetes. ... Potassium permanganate;

  5. Diabetes medication - Wikipedia

    en.wikipedia.org/wiki/Diabetes_medication

    Drugs used in diabetes treat types of diabetes mellitus by decreasing glucose levels in the blood. With the exception of insulin , most GLP-1 receptor agonists ( liraglutide , exenatide , and others), and pramlintide , all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic agents.

  6. Cure for type-1 diabetes closer to reality through advances ...

    www.aol.com/cure-type-1-diabetes-closer...

    Studies with monkeys show that injecting high-insulin-producing forms of these cells into the animals can “cure” type-1 diabetes for about six months. Human trials are underway.

  7. Meglitinide - Wikipedia

    en.wikipedia.org/wiki/Meglitinide

    A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to meglitinide for the treatment of type 2 diabetes.